Company Filing History:
1 out of 87 
1 out of 1,350 
Years Active: 2025
Title: Elisabeth Gillespie: Innovator in Brain Cancer Treatment
Introduction
Elisabeth Gillespie is a notable inventor based in Horsham, PA (US), recognized for her contributions to medical science, particularly in the field of brain cancer treatment. With a focus on innovative therapies, she has developed methods that aim to improve patient outcomes in this challenging area of healthcare.
Latest Patents
Elisabeth holds a patent for a groundbreaking combination therapy to treat brain cancer. This patent outlines methods for evaluating biological samples from patients with brain cancer to identify specific miRNAs. The therapy involves administering interleukin-12 (IL-12), an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate-specific membrane antigen (PSMA), along with an anti-programmed cell death receptor 1 (PD-1) antibody. The treatment is tailored based on the expression levels of certain miRNAs and mRNA biomarkers, providing a personalized approach to combating brain cancer.
Career Highlights
Throughout her career, Elisabeth has worked with prominent companies in the pharmaceutical industry, including Inovio Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. Her experience in these organizations has contributed significantly to her expertise in developing innovative cancer therapies.
Collaborations
Elisabeth has collaborated with notable professionals in her field, including Amy-Lee Bredlau and Israel Lowy. These partnerships have enhanced her research and development efforts, leading to advancements in cancer treatment methodologies.
Conclusion
Elisabeth Gillespie's work in brain cancer treatment exemplifies the impact of innovation in medicine. Her patented methods and collaborations highlight her commitment to improving patient care through scientific advancements.